The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis
Authors:
- 6 April 2010
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 11 (3) , 237-246
Abstract
Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A5 and has a narrow therapeutic range with large inter-individual variability. CYP3A5*3 polymorphism is reported to be functional and may contribute to the inter-individual variability. The objective of this meta-analysis was to accurately estimate the effect of CYP3A5*3 allele on CsA dose-adjusted blood concentration. A computerized literature search was conducted in PubMed. A total of 12 and 6 studies meeting the inclusion criteria were, respectively, included in meta-analysis about dose-adjusted trough concentration (C0/D) and dose-adjusted peak concentration (C2/D). The combined weighted mean difference (WMD) between CYP3A5 expressers (*1/*3 + *1/*1) and non-expressers (*3/*3) was significant in C2/D (WMD=−12.73 (ng ml–1)/(mg kg–1), 95% confidence interval (CI) −25.23 to −0.22, P=0.046), whereas it was marginally significant in C0/D (WMD=−3.75 (ng ml–1)/(mg kg–1), 95% CI −7.58 to 0.07, P=0.054). Exclusion of an outlier study greatly increased the association of CYP3A5 polymorphism with C0/D to be significant (WMD=−4.92 (ng ml–1)/(mg kg–1), 95% CI: −8.27 to −1.58, P=0.011). This meta-analysis showed that CYP3A5*3 polymorphism is associated with CsA dose-adjusted concentration in renal transplant recipients. Patients carrying the CYP3A5*3/*3 genotype will require a lower dose of CsA to reach target levels compared with the CYP3A5*1/*1 or *1/*3 carriers.Keywords
This publication has 32 references indexed in Scilit:
- Influence of theMDR1haplotype andCYP3A5genotypes on cyclosporine blood level in Chinese renal transplant recipientsXenobiotica, 2009
- A Population Pharmacokinetic Model of Ciclosporin Applicable for Assisting Dose Management of Kidney Transplant RecipientsClinical Pharmacokinetics, 2009
- Meta‐Analysis of the Effect of MDR1 C3435T Polymorphism on Cyclosporine PharmacokineticsBasic & Clinical Pharmacology & Toxicology, 2008
- Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitorsAmerican Journal of Health-System Pharmacy, 2006
- Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipientsActa Pharmacologica Sinica, 2006
- THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Drug Metabolism and Disposition, 2006
- The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipientsKidney International, 2006
- The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patientsPharmacogenetics, 2004
- Development of a new outlier statistic for meta-analytic data.Journal of Applied Psychology, 1995
- Factors Influencing the Pharmacokinetics of Cyclosporine in ManTherapeutic Drug Monitoring, 1991